您的位置: 首页 > 农业专利 > 详情页

Pass through administration PCSK9 inhibitor and angptl3 inhibitor for treating hyperlipemia
专利权人:
리제너론 파아마슈티컬스, 인크.
发明人:
구사로바 빅토리아,그로마다 제스퍼,머피 앤드류 제이.
申请号:
KR1020187028068
公开号:
KR1020180118181A
申请日:
2017.03.01
申请国别(地区):
KR
年份:
2018
代理人:
摘要:
The present invention provides suffer from hypercholesterolemia for treating, whereinThe patient is not responding to, so as to suitably control by or it is intolerant to standard liposomal modify treat. Method of the invention, which provides, to be reduced at least one lipid parameter patient, by giving the antibody of the specific bond of therapeutically effective amount or the antibody angiogenin sample egg 3 (ANGPTL3) of its antigen-binding fragment albumen conversion subtilisin/kexin types 9 (PCSK9) and the specific binding of therapeutically effective amount. It can be used for treating disease such as hypercholesterolemia including familial hypercholesterolemia (FH) in conjunction with anti-PCSK9 antibody and anti-ANGPTL3 antibody, two heFH and hoFH, and hyperlipidemia, hyperlipoprotememia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, it is a kind of risk factor, such as cardiovascular disease for Dyslipidemia with prevention or treatment disease or illness.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充